Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 15 studies | 35% ± 16% | |
peripheral blood | 14 studies | 29% ± 10% | |
intestine | 12 studies | 26% ± 9% | |
brain | 10 studies | 28% ± 9% | |
kidney | 6 studies | 26% ± 7% | |
bone marrow | 5 studies | 25% ± 6% | |
liver | 5 studies | 32% ± 16% | |
lymph node | 4 studies | 37% ± 15% | |
breast | 4 studies | 26% ± 7% | |
eye | 3 studies | 24% ± 3% | |
uterus | 3 studies | 37% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 98% | 1863.55 | 565 / 578 | 99% | 147.84 | 1146 / 1155 |
skin | 99% | 2697.71 | 1788 / 1809 | 96% | 61.10 | 452 / 472 |
brain | 94% | 3077.53 | 2478 / 2642 | 99% | 106.65 | 701 / 705 |
prostate | 89% | 1153.36 | 219 / 245 | 95% | 47.86 | 479 / 502 |
intestine | 81% | 2233.32 | 778 / 966 | 100% | 135.37 | 526 / 527 |
kidney | 99% | 2026.48 | 88 / 89 | 81% | 44.25 | 729 / 901 |
stomach | 80% | 1559.06 | 286 / 359 | 99% | 123.92 | 282 / 286 |
adrenal gland | 100% | 2230.77 | 258 / 258 | 77% | 38.18 | 178 / 230 |
breast | 78% | 810.38 | 357 / 459 | 98% | 125.19 | 1101 / 1118 |
bladder | 76% | 1103.52 | 16 / 21 | 99% | 201.63 | 501 / 504 |
esophagus | 61% | 2451.72 | 884 / 1445 | 100% | 119.58 | 183 / 183 |
uterus | 46% | 444.95 | 78 / 170 | 100% | 192.82 | 457 / 459 |
ovary | 42% | 350.53 | 75 / 180 | 97% | 74.09 | 415 / 430 |
thymus | 59% | 522.42 | 384 / 653 | 72% | 36.94 | 434 / 605 |
liver | 54% | 604.06 | 122 / 226 | 71% | 40.62 | 289 / 406 |
pancreas | 19% | 180.88 | 62 / 328 | 96% | 143.26 | 170 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 179.58 | 29 / 29 |
spleen | 100% | 3237.30 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 141.43 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 247.71 | 1 / 1 |
peripheral blood | 100% | 7173.29 | 926 / 929 | 0% | 0 | 0 / 0 |
muscle | 100% | 2600.05 | 800 / 803 | 0% | 0 | 0 / 0 |
adipose | 71% | 706.31 | 858 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 61% | 18.67 | 49 / 80 |
heart | 40% | 358.97 | 346 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 32% | 294.95 | 422 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0005829 | Cellular component | cytosol |
GO_0015630 | Cellular component | microtubule cytoskeleton |
GO_0045171 | Cellular component | intercellular bridge |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | JPT1 |
Protein name | Jupiter microtubule associated homolog 1 Jupiter microtubule associated homolog 1 (Androgen-regulated protein 2) (Hematological and neurological expressed 1 protein) [Cleaved into: Jupiter microtubule associated homolog 1, N-terminally processed] |
Synonyms | ARM2 HN1 |
Description | FUNCTION: Modulates negatively AKT-mediated GSK3B signaling . Induces CTNNB1 'Ser-33' phosphorylation and degradation through the suppression of the inhibitory 'Ser-9' phosphorylation of GSK3B, which represses the function of the APC:CTNNB1:GSK3B complex and the interaction with CDH1/E-cadherin in adherent junctions . Plays a role in the regulation of cell cycle and cell adhesion . Has an inhibitory role on AR-signaling pathway through the induction of receptor proteasomal degradation . . |
Accessions | ENST00000581874.1 ENST00000482348.5 [Q9UK76-3] ENST00000304834.11 ENST00000580380.1 J3KSH8 J3KT51 ENST00000409753.8 [Q9UK76-1] ENST00000481647.5 [Q9UK76-3] ENST00000470924.5 [Q9UK76-3] F2Z3M5 Q9UK76 ENST00000356033.8 [Q9UK76-2] ENST00000476258.5 [Q9UK76-3] |